Bioavailability of Dipyridamole After Asasantin (Extended Release 200mg Dipyridamole/25mg ASA) in 3 Experimental Formulations (Given b.i.d. Over 3 or 5 Days, Respectively) Relative to the Standard Formulation in 16 Healthy Female and Male Subjects. Intraindividual Comparison, Randomised, Open
Latest Information Update: 28 Oct 2014
At a glance
- Drugs Aspirin/dipyridamole (Primary)
- Indications Stroke; Transient ischaemic attacks
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 28 Oct 2014 New trial record